With the new school year underway, the Bibb County School District is turning to a familiar face to tackle a persistent ...

Denali Therapeutics (DNLI) reported a second-quarter 2025 loss of 72 cents per share, narrower than the Zacks Consensus Estimate of a loss of 74 cents. The company reported a loss of 59 cents in the ...

Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...

Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab) has shown continued benefit over four years, according ...

The study will assess the efficacy and safety of zorevunersen compared to sham over a 52-week treatment period.

With consumers struggling to differentiate between credible and unreliable medical information online, Medistry LLC's premium .med Top Level Domain (TLD) is poised to help.

In the EMPEROR trial, children with a confirmed variant in the SCN1A gene not associated with gain-of-function mutations will receive zorevunersen or a placebo.